Seattle Genetics Announces Collaboration with Pfizer

Seattle Genetics, Inc. SGEN announced today that it has entered into a collaboration agreement with Pfizer Inc. PFE under which Pfizer will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.